Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 8/20 | 0.91 |
| ▸ | HPGD | P15428 | 4/20 | 0.53 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.53 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.53 |
| ▸ | PIM1 | P11309 | 1/20 | 0.53 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.53 |
| ▸ | CISD1 | Q9NZ45 | 2/20 | 0.52 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2177332 | 0.95 | PPARG (1.00) | PPARGHPGDHDAC4HDAC8PIM1 | |
| SCHEMBL12520491 | 0.95 | PPARG (1.00) | PPARGHPGDHDAC4HDAC8PIM1 | |
| SCHEMBL2177329 | 0.95 | PPARG (1.00) | PPARGHPGDHDAC4HDAC8PIM1 | |
| SCHEMBL12521729 | 0.86 | PPARG (1.00) | PPARGHPGDHDAC4HDAC8PIM1 | |
| SCHEMBL12521723 | 0.85 | PPARG (0.78) | PPARGHPGDHDAC4HDAC8PIM1 | |
| SCHEMBL2177341 | 0.85 | PPARG (0.81) | PPARGHDAC4HDAC8 | |
| SCHEMBL2178690 | 0.83 | PPARG (0.80) | PPARGHPGD | |
| SCHEMBL1847312 | 0.83 | PPARG (0.80) | PPARGHPGD | |
| SCHEMBL1848112 | 0.81 | PPARG (0.61) | PPARGHPGDPIM1PIM2CISD1 | |
| SCHEMBL1848111 | 0.81 | PPARG (0.61) | PPARGHPGDPIM1PIM2CISD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011091033-A1 | MODULATION OF NEUROGENESIS BY PPAR AGENTS | BRAINCELLS, INC. (US) | 2011-07-28 | — | — | WO | disclosed |
| US-20100184806-A1 | MODULATION OF NEUROGENESIS BY PPAR AGENTS | BRAINCELLS, INC. (US) | 2010-07-22 | — | — | US | disclosed |
| US-20100184806-A1 | MODULATION OF NEUROGENESIS BY PPAR AGENTS | BRAINCELLS, INC. (US) | 2010-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100184806-A1 | MODULATION OF NEUROGENESIS BY PPAR AGENTS | PPARG, PPARA, PPARD | PPARG 1/4885HPGD 1116/4885HDAC4 391/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.